Literature DB >> 17764917

Cisplatin-induced nephrotoxicity causes altered renal hemodynamics in Wistar Kyoto and spontaneously hypertensive rats: role of augmented renal alpha-adrenergic responsiveness.

Md Abdul Hye Khan1, Munavvar Abdul Sattar, Nor Azizan Abdullah, Edward James Johns.   

Abstract

The pathogenesis of cisplatin-induced renal failure is related to reduced renal blood flow due to severe tubular damage and enhanced renovascular resistance. It is also known that alpha(1)-adrenoceptors, the major subtype of alpha-adrenoceptors in renal vasculature play the pivotal role in regulating renal hemodynamics. With this background, we have hypothesized that the altered renal hemodynamics and enhanced renovascular resistance in cisplatin-induced renal failure might be caused by the altered alpha-adrenergic responsiveness with a possible involvement of alpha(1)-adrenoceptors in the renal vasculature. In a unique experimental approach with anesthetized rats, this study has therefore examined if there is any shift in the renovascular responsiveness to renal nerve stimulation and a series of alpha-adrenergic agonists in Wistar Kyoto (WKY) and spontaneously hypertensive (SHR) rats with cisplatin-induced renal failure in comparison with their body weight-matched normal controls. Thirty-two male rats of both WKY (n=16) and SHR (n=16) origin with body weight 236+/-7.9 g received cisplatin (5mg/kg i.p.). The renal failure was confirmed in terms of significantly reduced renal blood flow, reduced creatinine clearance, increased fractional excretion of sodium, increased kidney index (all P<0.05) and tubular damage. After 7 days of cisplatin, the overnight fasted rats were anesthetized (sodium pentobarbitone, 60 mg/kg i.p.) and renal vasoconstrictor experiments were done. The changes in the vasoconstrictor responses were determined in terms of reductions in renal blood flow caused by electrical renal nerve stimulation or intrarenal administration of noradrenaline, phenylephrine and methoxamine. It was observed that in the cisplatin-treated renal failure WKY and SHR rats there were significant (all P<0.05) reductions in the renal blood flow along with significantly (P<0.05) higher renal adrenergic responsiveness as compared with their non-renal failure controls. The data showed that in the renal failure WKY and SHR rats, the altered renal hemodynamics might be caused by an augmented renal adrenergic responsiveness. The results obtained further led us to suggest that the augmented renal adrenergic responsiveness in the cisplatin-induced renal failure rats were possibly mediated by the alpha(1)-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17764917     DOI: 10.1016/j.etp.2007.05.005

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  4 in total

1.  Perindopril regulates the inflammatory mediators, NF-κB/TNF-α/IL-6, and apoptosis in cisplatin-induced renal dysfunction.

Authors:  Abdel-Gawad S Shalkami; Mohamed I A Hassan; Ahmed A Abd El-Ghany
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-31       Impact factor: 3.000

2.  Influence of combined hypertension and renal failure on functional alpha(1)-adrenoceptor subtypes in the rat kidney.

Authors:  M A Hye Khan; M A Sattar; N A Abdullah; E J Johns
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

Review 3.  Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi Jazi; Bahar Mazaheri; Maryam Moeini; Tahereh Safari; Fariba Azarkish; Fatemeh Moslemi; Maryam Maleki; Alireza Rezaei; Shadan Saberi; Aghdas Dehghani; Maryam Malek; Azam Mansouri; Marzieh Ghasemi; Farzaneh Zeinali; Zohreh Zamani; Mitra Navidi; Sima Jilanchi; Soheyla Shirdavani; Farzaneh Ashrafi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

4.  Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats.

Authors:  Sudeshna Fisch; Ronglih Liao; Li-Li Hsiao; Tzongshi Lu
Journal:  J Vis Exp       Date:  2016-03-11       Impact factor: 1.355

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.